A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Trial Profile

A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs RAD 140 (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 29 Sep 2017 According to a Radius Health media release, the first patient has been enrolled in this trial. Additional details are anticipated in peer-reviewed publications and results are anticipated at upcoming scientific conferences.
    • 29 Sep 2017 Status changed from not yet recruiting to recruiting, as reported in a Radius Health Inc. media release.
    • 03 Aug 2017 According to a Radius Health media release, the US FDA has accepted an Investigational New Drug (IND) application for RAD-140 and the company expects to initiate this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top